Hungarian Egis to develop pharmaceutical market of Uzbekistan

Egis Pharmaceuticals has agreed to cooperate with the Pharmaceutical Industry Development Agency of Uzbekistan, Hungary Today reports.

Under the terms of the agreement, the Hungarian drug manufacturer will assist in the development of standards to regulate the country’s drug industry. It will also provide the regulator with assistance in improving the skills of employees.

One of the main aspects of cooperation will be the regular exchange of knowledge and experience. In the face of difficulties with quality assurance, such information is of particular importance for the Uzbek pharmaceutical industry, the company noted.

“Egis is confident in the long-term development of the pharmaceutical market in Uzbekistan, given the rapid growth of the country’s population and economy,” the statement reads.

The industry’s annual turnover is estimated at approximately $1.6 billion. The country’s authorities pay considerable attention to ensuring access to quality medicines.

Earlier, Spot wrote that the Russian Geropharm terminated the agreement with its Uzbek partner on the production of insulin and is looking for a replacement.

Egis Pharmaceuticals Zrt. deals with the full cycle of drug production from research to production, sales and export to 62 countries. The company dates its history back to 1913, and in 1933 it opened its first laboratory in Budapest. Since 1995, Egis has been part of the French Servier Group.